Altimmune initiated with a Buy at Truist

Truist initiated coverage of Altimmune (ALT) with a Buy rating and $12 price target The firm believes that Altimmune’s lead asset, pemvidutide, “could be successful in treating MASH as well as liver-related diseases AUD.” Truist is modelling peak ~20K patients on pemvidutide, which would result in worldwide “peak adjusted/unadjusted revenue of ~$600M/$1.0B.”